1. Home
  2. CKPT

CKPT

Checkpoint Therapeutics Inc.

Logo Checkpoint Therapeutics Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-19-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.

Founded: 2014 Country:
United States
United States
Employees: N/A City: WALTHAM
Market Cap: 63.5M IPO Year: 2017
Target Price: $22.60 AVG Volume (30 days): 496.4K
Analyst Decision: Strong Buy Number of Analysts: 5
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -3.17 EPS Growth: N/A
52 Week Low/High: $1.30 - $3.62 Next Earning Date: 05-13-2024
Revenue: $103,000 Revenue Growth: -46.35%
Revenue Growth (this year): 687.28% Revenue Growth (next year): 5912.58%

Share on Social Networks: